28th Jul 2026 15:27
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
----------
Niox Group PLC - Oxford, England-based medical device developer - Expects revenue of GBP24.0 million in the six months ended June 30, down from GBP25.2 million the year prior. Clinical revenue rises to GBP20.6 million from GBP20.0 million, reflecting the timing of Niox Pro regulatory approvals but research sales decline to GBP3.4 million from GBP5.2 million following the strategic decision to prioritise inventory within the clinical business. Gross margin improves to 71% from 70% on-year, reflecting a higher mix of Clinical sales. Adjusted earnings before interest, tax, depreciation and amortisation falls to GBP8.3 million from GBP9.2 million. Niox says full-year trading is in line with consensus market expectations and that it intends to return excess capital to shareholders during the second half of 2026.
----------
Creo Medical Group PLC - Chepstow, Wales-based medical device company - Says it continued to make strong operational and strategic progress through the second quarter of the financial year. Half-year revenue increases 45% to GBP3.2 million from GBP2.2 million. "Trading for the period was in line with management expectations, supporting the board's confidence in delivering full year revenue growth in line with existing guidance of 50% to 60%. This full year guidance is underpinned by a strong order book carried into Q3-26, the group's usual H2-weighted revenue profile and continued expansion into new regions, particularly in [Latin America]." Underlying operating costs in the first half decrease by 15% to GBP7.8 million from GBP9.1 million, and the underlying operating loss on a continuing basis reduces by over 25% in to GBP4.9 million from GBP6.9 million. "With growing clinical and commercial momentum across the portfolio, we remain well placed for the second half and confident in delivering our full year guidance," says Chief Executive Craig Gulliford.
----------
Kistos Holdings PLC - London-based oil and gas producer from offshore and onshore assets in the UK, Norway, and the Netherlands - Pro forma production totals 20,500 barrels of oil equivalent per day in the first half of 2026 and Kistos retains full-year guidance for production at 19,000 to 21,000 boepd.
Pro forma Ebitda is USD205 million in the period, with non-pro forma basis Ebitda USD155 million. Cash at June is USD259 million and adjusted net debt USD23 million. "We continue to see a range of M&A opportunities across our core geographies, we continue to focus on value accretive opportunities, and believe our track record and ability to execute transactions makes us an attractive counterparty to work with," says Executive Chair Andrew Austin.
----------
dotdigital Group PLC - London-based customer experience and data platform provider - Says revenue, adjusted pretax profit and cash are in line with FY26 market expectations of GBP92.3 million, GBP19.7 million and GBP16.3 million respectively. Forward-looking contracted annual recurring revenue grows 18% to GBP85.4 million from GBP72.6 million, or 8% organically, with organic growth improving from 6% at the half year. Recognised recurring revenue rises 14% to GBP76.8 million from GBP67.3 million, or 3% organically. "The Group enters FY27 with a larger contracted recurring-revenue base, improved revenue visibility and a broader opportunity to accelerate organic growth over the medium term," it says.
----------
Restore PLC - London-based business-to-business provider of data and communications services - Pretax profit rises 28% to GBP7.4 million in the half year ended June 30 from GBP5.8 million with revenue up 21% to GBP175.4 million from GBP144.4 million. Sales growth is driven by both organic and inorganic growth in broadly equal proportions. Basic earnings per share total 3.6 pence, up 38% from 2.6p. The dividend is hiked 18% to 2.6p per share from 2.2p. "The combination of recurring revenues, strong operating margins and predictable strong cash generation, combined with our organic growth opportunities, provides an excellent platform for delivering further shareholder value. We are well positioned to continue to deliver both organic and inorganic revenue and profit growth," company says. Restore says it remains confident of delivering adjusted pretax profit for the full year at least in line with market expectations with consensus put at GBP47.2 million. In addition, says Chief Executive Officer Charles Skinner will move to the role of non-executive chair. Skinner will be succeeded as CEO by Dan Baker, who has served as chief financial officer since 2023. The changes are effective from January 1.
----------
Staffline Group PLC - Nottingham, England-based flexible staff recruiter in the UK and Ireland - Pretax profit balloons to GBP2.9 million in the six months ended June 30 from GBP600,000 the year prior. Revenue increases 15% to GBP559.4 million from GBP485.8 million with gross profit GBP37.5 million, up 13% from GBP33.1 million. EPS is 1.9 pence versus 0.3p a year ago. Revenue growth is driven by new contract wins and expanded mandates with existing customers. Says strong trading momentum continues into the second half leaving the group well positioned to deliver FY 2026 towards the top end of current market expectations.
----------
Uniphar PLC - Dublin-based healthcare services company - Achieves around 11% adjusted EPS growth in the first half of 2026, in line with expectations, driven by a strong trading performance with 7% organic gross profit growth. By division, Uniphar Pharma delivers high single-digit organic gross profit growth during the period and is on track to deliver double-digit organic gross profit growth for the full year. Uniphar Medtech achieves high single-digit organic gross profit growth during the half and remains on track to deliver high single-digit organic gross profit growth for the full year. While Uniphar Supply Chain & Retail delivers mid-single-digit organic gross profit growth during the half and is expected to deliver mid-single-digit organic gross profit growth for the full year. "Uniphar enters the second half of the year with strong trading momentum across the group, and underlying trading expectations for the year remain unchanged," the firm adds.
----------
By Jeremy Cutler, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Niox GroupCreo MedicalKistos HoldingsdotDigital GroupRestoreStafflineUniphar